Locally Advanced Cervical Cancer Clinical Trial
Official title:
Predictors of Para-aortic Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer Based on the Pooled Analysis of Surgical Staging Results
NCT number | NCT05717751 |
Other study ID # | CQGOG0110 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 13, 2022 |
Est. completion date | December 12, 2022 |
Verified date | January 2023 |
Source | Chongqing University Cancer Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The goal of this observational study is to identify predictive factors and to develop a risk model predicting para-aortic lymph node metastasis in patients with locally advanced cervical cancer based on the analysis of surgical staging results. The main questions it aims to answer are: - What are the risk factors to predict para-aortic lymph node metastasis in patients with locally advanced cervical cancer? - What is the indication for prophylactic extended-field radiation therapy in patients with locally advanced cervical cancer Individual data of patients with locally advanced cervical cancer treated with surgical staging at our institution from 2020 to 2022 were pooled analysed.Multivariate Logistic regression analysis was used to identify the predictive factors and to develop the prediction model.
Status | Completed |
Enrollment | 452 |
Est. completion date | December 12, 2022 |
Est. primary completion date | November 12, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - In 2018, the International Federation of Obstetrics and Gynecology (FIGO) stage was Ib3 IIA2-IVA; - It was treated initially without surgical and chemotherapy. - Squamous cell carcinoma, adenocarcinoma and adeno-squamous cell carcinoma were confirmed by histopathology. - Abdominal pelvic CT, MRI or PET/CT were performed before treatment. - Patients with successful surgical staging and the pathological data of para-aortic lymph node were obtained. Exclusion Criteria: - Patients were excluded if the histopathological type was not squamous cell carcinoma or Adenocarcinoma, and the data of LN status was not available. |
Country | Name | City | State |
---|---|---|---|
China | Chongqing University Cancer Hospital | Chongqing | Chongqing |
Lead Sponsor | Collaborator |
---|---|
Chongqing University Cancer Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Predictors of para-aortic lymph node metastasis | We evaluate the institutional database for medical records to identify patients who underwent surgical staging, then comprised the primary and the independent validation cohort, respectively. The variables were collected from each patient. We assess the bivariate relationship between each variable and para-aortic lymph node metastasis via logistic regression analysis. The potential predictive variables of a P-value<0.05 on univariate analysis were considered as risk factors. | 3 months | |
Primary | The prediction model of para-aortic lymph node metastasis | The multivariable logistic regression analysis between predictors and para-aortic lymph node metastasis was conducted and evaluated odds ratio. To facilitate practical application, a score chart was developed to present the final prediction model. The risk score of predictive variables were calculated and rounded based on its beta-coefficients from the multivariate logistic regression analysis. The prediction model was then developed by combining all scores, and the sum of scores for each predictor represented the risk score for every patient. | 3 months | |
Secondary | validation of the prediction model | We adopted an internal and independent validation to assess the performance of the prediction model.The internal validation of the model was performed with respect to discrimination which was measured by the concordance index and calibration which was assessed by the Hosmer-Lemeshow test and Brier score. The independent validation was performed with respect to sensitivity, specificity and Youden index, which calculated by sensitivity+specificity-1 is a global measure of diagnostic effectiveness. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03225443 -
Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT06079671 -
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
|
Phase 3 | |
Completed |
NCT05059119 -
Rectovaginal Fistula in Post-Radiotherapy Advanced Cervical Cancer Patients
|
||
Recruiting |
NCT06055738 -
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
|
Phase 2 | |
Recruiting |
NCT06156514 -
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
|
Phase 3 | |
Completed |
NCT03298893 -
Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01514955 -
An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer
|
Phase 1 | |
Recruiting |
NCT05950087 -
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
|
||
Recruiting |
NCT04884906 -
Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05799469 -
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
Terminated |
NCT02045433 -
Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT06237257 -
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06288373 -
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06288360 -
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
|
Phase 2 | |
Recruiting |
NCT06068387 -
A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis
|
N/A | |
Recruiting |
NCT05378087 -
Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer
|
N/A | |
Recruiting |
NCT03963882 -
NAC Followed by RH for the Treatment of LACC
|
Phase 2 | |
Recruiting |
NCT01938105 -
Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01793701 -
Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer
|
Phase 1/Phase 2 |